Rituximab improves response to treatment and outcome for patients with CD20+ B-cell lymphoma. Herein, however, we report the occurrence of severe pulmonary complications shortly after rituximab infusion in three patients with the newly diagnosed Asian variant of intravascular lymphoma. It is suggested that patients with this subtype of lymphoma are monitored carefully for possible drug reactions during the use of rituximab.

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.10561DOI Listing

Publication Analysis

Top Keywords

severe pulmonary
8
pulmonary complications
8
intravascular lymphoma
8
complications initial
4
initial treatment
4
rituximab
4
treatment rituximab
4
rituximab asian-variant
4
asian-variant intravascular
4
lymphoma
4

Similar Publications

Background: Asthma is currently one of the most common of respiratory diseases, severely affecting the lives of patients. With the in-depth study of the role of the nervous system and sex hormones on the development of asthma, it has been found that the nervous system and sex hormones are related to each other in the pathway of asthma.

Objective: To investigate the effects of sex hormones and the nervous system on the development of asthma.

View Article and Find Full Text PDF

Interhospital Variability in 180-day Infections Following Cardiac Surgery.

J Thorac Cardiovasc Surg

January 2025

Department of Cardiac Surgery, University of Michigan Medical School, Ann Arbor, MI, 48109; Michigan Society of Thoracic and Cardiovascular Surgeons Quality Collaborative, Ann Arbor, MI 48109. Electronic address:

Objective: This study sought to: (1) evaluate hospital-level variation in infections following cardiac surgery and (2) develop and evaluate a 180-day infection quality metric.

Methods: This study evaluated Medicare claims that were merged with institutional Society of Thoracic Surgeons Adult Cardiac Surgery Database files among patients undergoing cardiac surgery across 33 Michigan centers. The primary outcome was an infection within 180 days of surgery.

View Article and Find Full Text PDF

Background: COVID-19 is associated with intense systemic inflammation and abnormal coagulation profile leading to an increased incidence of pulmonary embolism (PE). This study investigates whether PE in COVID-19 patients has different clinical, laboratory and radiological characteristics when compared to traditional PE in COVID negative patients.

Methods: We conducted an observational, multicentric, cross-sectional study on consecutive patients diagnosed with PE at admission or during hospital stay from February 21 2019 to February 20 2021.

View Article and Find Full Text PDF

Acute pulmonary embolism with and without hemodynamic instability (2003-2022): A Swiss nationwide epidemiological study.

J Thromb Haemost

January 2025

Department of Angiology, University Hospital Zurich, University of Zurich, Switzerland; Center for Thrombosis and Hemostasis, University Hospital of the Johannes Gutenberg University Mainz, Mainz, Germany.

Background: Data on the epidemiological burden of acute pulmonary embolism (PE) in Switzerland is unavailable. Knowledge gaps remain on trends in PE-related comorbidities, PE severity, and length of in-hospital stay (LOS) at a nationwide level.

Methods: We used nationwide, patient-level data including all patients aged 15 years or older hospitalized for PE in Switzerland from 2003 to 2022, amounting to N=180,600.

View Article and Find Full Text PDF

The growing issue of drug resistance, particularly multidrug-resistant TB (MDR-TB), has exacerbated this problem. The rise of drug resistance TB is a severe global health concern. In Thailand, a persistent community outbreak of primary MDR-TB has been confirmed in the Tha Maka district of Kanchanaburi province, with an increasing prevalence of MDR-TB among newly diagnosed pulmonary tuberculosis cases.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!